Ramakrishnan Rajagopalan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ramakrishnan Rajagopalan has a total of 744 co-authors. Here are the top co-authors by number of shared publications:
Gail P. Jarvik
Department of Medicine (Medical Genetics), University of Washington, Seattle, Wash
10 shared publications- Alan R. Shuldiner
Regeneron Genetics Center, Tarrytown, USA
7 shared publications - Alice Stanton
Royal College of Surgeons in Ireland, Dublin, Ireland
7 shared publications Barbara Thorand
7 shared publications- Braxton D. Mitchell
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
7 shared publications - Cisca Wijmenga
Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
7 shared publications
Latest Publications
- Open Access
Overcoming a diagnostic blindspot: Identifying balanced translocations in Mendelian rare disease cohorts
Background: Short-read genome sequencing generates the signal necessary to detect balanced reciprocal translocations at single-nucleotide resolution, but standard structural variant callers represent them as breakend pairs. Structural variant callers produce thousands of breakend records per genome, the majority of which are false positives arising from segmental duplications, repetitive elements, and reference assembly artifacts. This specificity problem has prevented balanced translocation detection from entering routine genome sequencing workflows. We developed a highly specific pipeline to resolve balanced reciprocal translocations and applied it across five clinically distinct cohorts to characterize the prevalence and diagnostic contribution of balanced reciprocal translocations. Methods: Short-read genome sequencing data from 16,131 individuals across five cohorts were analyzed: healthy participants from the 1000 Genomes Project (n=3,202), probands with structural birth defects and their family members (CHOP BDB cohort; n=2,875, including 1017 probands), probands enrolled in the GREGoR consortium (GREGoR cohort; n=3,574 probands), probands with undiagnosed disease and their family members enrolled in the Undiagnosed Diseases Network (UDN cohort; n=6,071 including 2,027 probands) and neonates who underwent rapid genome sequencing (CHOP Baby Eagle cohort; n=409). A computational pipeline was developed to characterize breakend events from standard structural variant callers to high-confidence balanced translocation calls by exploiting well-characterized properties of true balanced translocation signatures in short-read data. Translocation breakpoints were resolved to single-nucleotide precision and interrogated for disruption of known disease genes or potential regulatory consequence otherwise. A subset of the identified breakpoints was confirmed by Sanger sequencing. Results: Balanced reciprocal translocations were identified in 0.196% of structural birth defect probands (2/1,017), 0.25% of the GREGoR probands (9/3,574), 0.39% of the UDN probands (8/2,027) and 0.24% of neonates who underwent rapid genome sequencing (1/409). Parental carrier frequency in the birth defects cohort was 0.269% (5/1,858), consistent with previously reported estimates in similarly ascertained families, and 0.098% (3/3,040) in the UDN cohort. All six translocations identified in the birth defects cohort were orthogonally validated using Sanger sequencing, confirming pipeline specificity. Approximately 31% of translocations across the three affected cohorts disrupted a known disease gene at the breakpoint, establishing or refining a molecular diagnosis in five cases previously unresolved. The single translocation identified in the newborn cohort disrupted no disease gene and was classified as a variant of uncertain significance.
Open AccessOvercoming a diagnostic blindspot: Identifying balanced translocations in Mendelian rare disease cohorts
Background: Short-read genome sequencing generates the signal necessary to detect balanced reciprocal translocations at single-nucleotide resolution, but standard structural variant callers represent them as breakend pairs. Structural variant callers produce thousands of breakend records per genome, the majority of which are false positives arising from segmental duplications, repetitive elements, and reference assembly artifacts. This specificity problem has prevented balanced translocation detection from entering routine genome sequencing workflows. We developed a highly specific pipeline to resolve balanced reciprocal translocations and applied it across five clinically distinct cohorts to characterize the prevalence and diagnostic contribution of balanced reciprocal translocations. Methods: Short-read genome sequencing data from 16,131 individuals across five cohorts were analyzed: healthy participants from the 1000 Genomes Project (n=3,202), probands with structural birth defects and their family members (CHOP BDB cohort; n=2,875, including 1017 probands), probands enrolled in the GREGoR consortium (GREGoR cohort; n=3,574 probands), probands with undiagnosed disease and their family members enrolled in the Undiagnosed Diseases Network (UDN cohort; n=6,071 including 2,027 probands) and neonates who underwent rapid genome sequencing (CHOP Baby Eagle cohort; n=409). A computational pipeline was developed to characterize breakend events from standard structural variant callers to high-confidence balanced translocation calls by exploiting well-characterized properties of true balanced translocation signatures in short-read data. Translocation breakpoints were resolved to single-nucleotide precision and interrogated for disruption of known disease genes or potential regulatory consequence otherwise. A subset of the identified breakpoints was confirmed by Sanger sequencing. Results: Balanced reciprocal translocations were identified in 0.196% of structural birth defect probands (2/1,017), 0.25% of the GREGoR probands (9/3,574), 0.39% of the UDN probands (8/2,027) and 0.24% of neonates who underwent rapid genome sequencing (1/409). Parental carrier frequency in the birth defects cohort was 0.269% (5/1,858), consistent with previously reported estimates in similarly ascertained families, and 0.098% (3/3,040) in the UDN cohort. All six translocations identified in the birth defects cohort were orthogonally validated using Sanger sequencing, confirming pipeline specificity. Approximately 31% of translocations across the three affected cohorts disrupted a known disease gene at the breakpoint, establishing or refining a molecular diagnosis in five cases previously unresolved. The single translocation identified in the newborn cohort disrupted no disease gene and was classified as a variant of uncertain significance.
- Open Access
Characterization of Large-Scale Mitochondrial DNA Rearrangements Using Complementary Short- and Long-Read Sequencing Approaches
Background: Large-scale mitochondrial DNA (mtDNA) rearrangement, including deletion or duplication, is one of the important causes of primary mitochondrial disease. In clinical practice, short-read sequencing (SRS)-based assays typically detect these rearrangements by identifying regional mtDNA copy-number changes but generally do not directly distinguish deletions from duplications. As a result, mtDNA duplications may be misclassified as deletions, potentially leading to inaccurate molecular diagnoses and genotype–phenotype correlations. This study aimed to evaluate the utility of long-read sequencing (LRS) for the definitive characterization of large-scale mtDNA rearrangements. Methods: Two individuals who had been reported to possess single large-scale mtDNA deletions using SRS-based clinical tests were re-evaluated because their clinical presentations were not consistent with typical mtDNA deletion syndromes. Existing SRS data were reanalyzed, and the suspected rearrangements were independently characterized using both Pacific Biosciences (PacBio) and Oxford Nanopore Technologies long-read sequencing platforms. Results: Reanalysis of SRS data suggested that the reported deletions were more consistent with mtDNA duplications. This finding was confirmed by both PacBio and Oxford Nanopore LRS in one case. Reclassifying the deletion to a duplication in this case substantially improved genotype–phenotype interpretation and better explained the atypical clinical features observed in this individual. However, LRS could not capture sufficient long reads that give direct evidence of duplication in the second case due to low heteroplasmy of the mtDNA structural variant. Therefore, this case remains inconclusive. Conclusions: SRS and LRS provide complementary information for the evaluation of large-scale mtDNA rearrangements. SRS can sensitively identify mtDNA large deletions, but it cannot distinguish mtDNA deletion from duplication. On the other hand, LRS can provide direct structural information and confirm duplication. However, LRS may have limited sensitivity for low-level heteroplasmic structural variants. An integrated approach incorporating both methods, together with clinical correlation and reanalysis of potentially discordant findings, may improve the characterization and interpretation of mtDNA rearrangements.
Open AccessCharacterization of Large-Scale Mitochondrial DNA Rearrangements Using Complementary Short- and Long-Read Sequencing Approaches
Background: Large-scale mitochondrial DNA (mtDNA) rearrangement, including deletion or duplication, is one of the important causes of primary mitochondrial disease. In clinical practice, short-read sequencing (SRS)-based assays typically detect these rearrangements by identifying regional mtDNA copy-number changes but generally do not directly distinguish deletions from duplications. As a result, mtDNA duplications may be misclassified as deletions, potentially leading to inaccurate molecular diagnoses and genotype–phenotype correlations. This study aimed to evaluate the utility of long-read sequencing (LRS) for the definitive characterization of large-scale mtDNA rearrangements. Methods: Two individuals who had been reported to possess single large-scale mtDNA deletions using SRS-based clinical tests were re-evaluated because their clinical presentations were not consistent with typical mtDNA deletion syndromes. Existing SRS data were reanalyzed, and the suspected rearrangements were independently characterized using both Pacific Biosciences (PacBio) and Oxford Nanopore Technologies long-read sequencing platforms. Results: Reanalysis of SRS data suggested that the reported deletions were more consistent with mtDNA duplications. This finding was confirmed by both PacBio and Oxford Nanopore LRS in one case. Reclassifying the deletion to a duplication in this case substantially improved genotype–phenotype interpretation and better explained the atypical clinical features observed in this individual. However, LRS could not capture sufficient long reads that give direct evidence of duplication in the second case due to low heteroplasmy of the mtDNA structural variant. Therefore, this case remains inconclusive. Conclusions: SRS and LRS provide complementary information for the evaluation of large-scale mtDNA rearrangements. SRS can sensitively identify mtDNA large deletions, but it cannot distinguish mtDNA deletion from duplication. On the other hand, LRS can provide direct structural information and confirm duplication. However, LRS may have limited sensitivity for low-level heteroplasmic structural variants. An integrated approach incorporating both methods, together with clinical correlation and reanalysis of potentially discordant findings, may improve the characterization and interpretation of mtDNA rearrangements.
- Open Access
- 12 August 2026
- Published by Springer Nature in npj Genomic Medicine
Multi-omic re-analysis increases diagnostic yield in individuals with Cornelia de Lange syndrome
- 12 August 2026
- Published by Springer Nature in npj Genomic Medicine
Open AccessMulti-omic re-analysis increases diagnostic yield in individuals with Cornelia de Lange syndrome
- Open Access
- 16 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (8) , 3562
Evaluation of PacBio Long-Read and PCR-Based Short-Read Sequencing for Mitochondrial DNA (mtDNA) Variant Detection, with an Emphasis on Detection and Quantification of mtDNA Deletion
Accurate detection of all types of mitochondrial DNA (mtDNA) variants, including single large-scale mtDNA deletions (SLSMDs) and multiple mtDNA deletions (MMDs), along with heteroplasmy quantification, is essential for Primary Mitochondrial Disease (PMD) diagnosis. This study compares amplification-free PacBio long-read sequencing (LRS) mtDNA analysis with long-range PCR-based targeted mtDNA sequencing by short-read sequencing (SRS) in terms of detection sensitivity and accuracy. In total, 17 samples, including 4 SLSMD cases (3 blood, 1 muscle), 9 MMD muscle samples, and 4 deletion-negative controls (1 blood, 3 muscle), were sequenced using the PacBio Sequel IIe. Our findings demonstrate LRS’s efficacy in detecting single nucleotide variants (SNVs) and large mtDNA deletions with precise breakpoints. LRS can accurately detect and distinguish SLSMD from MMD, providing deletion heteroplasmy without the need for a second methodology. Deletion heteroplasmy computed from LRS was highly correlated with the Droplet Digital PCR (ddPCR) estimates (Pearson’s r2 = 0.95). While LRS can detect SNVs with approximately 5% heteroplasmy, only variants exceeding 10% heteroplasmy can attain 100% sensitivity, specificity, and precision when compared to those previously identified through clinical testing. In conclusion, our findings establish PacBio LRS as a robust tool for comprehensive mtDNA analysis capable of accurately detecting and quantifying heteroplasmic mtDNA variants and complex deletions.
- 16 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (8) , 3562
Open AccessEvaluation of PacBio Long-Read and PCR-Based Short-Read Sequencing for Mitochondrial DNA (mtDNA) Variant Detection, with an Emphasis on Detection and Quantification of mtDNA Deletion
Accurate detection of all types of mitochondrial DNA (mtDNA) variants, including single large-scale mtDNA deletions (SLSMDs) and multiple mtDNA deletions (MMDs), along with heteroplasmy quantification, is essential for Primary Mitochondrial Disease (PMD) diagnosis. This study compares amplification-free PacBio long-read sequencing (LRS) mtDNA analysis with long-range PCR-based targeted mtDNA sequencing by short-read sequencing (SRS) in terms of detection sensitivity and accuracy. In total, 17 samples, including 4 SLSMD cases (3 blood, 1 muscle), 9 MMD muscle samples, and 4 deletion-negative controls (1 blood, 3 muscle), were sequenced using the PacBio Sequel IIe. Our findings demonstrate LRS’s efficacy in detecting single nucleotide variants (SNVs) and large mtDNA deletions with precise breakpoints. LRS can accurately detect and distinguish SLSMD from MMD, providing deletion heteroplasmy without the need for a second methodology. Deletion heteroplasmy computed from LRS was highly correlated with the Droplet Digital PCR (ddPCR) estimates (Pearson’s r2 = 0.95). While LRS can detect SNVs with approximately 5% heteroplasmy, only variants exceeding 10% heteroplasmy can attain 100% sensitivity, specificity, and precision when compared to those previously identified through clinical testing. In conclusion, our findings establish PacBio LRS as a robust tool for comprehensive mtDNA analysis capable of accurately detecting and quantifying heteroplasmic mtDNA variants and complex deletions.
- Open Access
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (5) , e200291
Deep Intronic SVA_E Insertion Identified as the Most Common Pathogenic Variant Associated With Canavan Disease
Canavan disease (CD) is a neurodegenerative disorder in which biallelic pathogenic variants in ASPA result in spongiform degeneration of the cerebral white matter, leading to progressive and irreversible motor and cognitive decline. Despite comprehensive genetic testing, many individuals with clinical and biochemical diagnoses of CD remain without a definitive molecular diagnosis. This gap hinders access to emerging gene-targeted therapies and limits participation in clinical trials. Our objective was to understand the genetic etiology of 8 unsolved cases of CD. We used long-read sequencing (LRS) to investigate 8 individuals clinically and biochemically diagnosed with CD but who had negative genetic testing results. We performed targeted LRS using the Oxford Nanopore Technologies platform for 3 unrelated individuals and PacBio HiFi for an additional individual from our cohort. We performed targeted LRS on barcoded and pooled samples from the remaining affected individuals. To investigate functional impact on gene function, we performed RNA sequencing (RNA-seq) with and without cycloheximide on fibroblasts. We then evaluated the allele frequency in the population using gnomAD. We identified an ∼2,600-bp SVA_E retrotransposon intronic insertion in ASPA in all 8 individuals. The insertion was found to be either homozygous or compound heterozygous trans with a known pathogenic variant in all individuals. RNA-seq indicated that the SVA_E insertion creates a novel splice acceptor site within intron 4 of ASPA that causes aberrant splicing and transcript degradation. Surprisingly, the frequency of this variant in population databases suggests that it is the most common pathogenic variant in ASPA and that it is present across ancestry groups. Our study identified the most common pathogenic variant in ASPA, which has been overlooked in 25 years of CD research. Considering this, it is important to ensure that all testing laboratories can detect this variant through diagnostic testing and carrier screening. Our study highlights a substantial blind spot in standard short-read diagnostic pipelines, which historically have missed or overlooked these types of insertions. It also shows the power of emerging technologies, such as LRS and RNA-seq, to identify new classes of variants for genetic disorders, including CD.
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (5) , e200291
Open AccessDeep Intronic SVA_E Insertion Identified as the Most Common Pathogenic Variant Associated With Canavan Disease
Canavan disease (CD) is a neurodegenerative disorder in which biallelic pathogenic variants in ASPA result in spongiform degeneration of the cerebral white matter, leading to progressive and irreversible motor and cognitive decline. Despite comprehensive genetic testing, many individuals with clinical and biochemical diagnoses of CD remain without a definitive molecular diagnosis. This gap hinders access to emerging gene-targeted therapies and limits participation in clinical trials. Our objective was to understand the genetic etiology of 8 unsolved cases of CD. We used long-read sequencing (LRS) to investigate 8 individuals clinically and biochemically diagnosed with CD but who had negative genetic testing results. We performed targeted LRS using the Oxford Nanopore Technologies platform for 3 unrelated individuals and PacBio HiFi for an additional individual from our cohort. We performed targeted LRS on barcoded and pooled samples from the remaining affected individuals. To investigate functional impact on gene function, we performed RNA sequencing (RNA-seq) with and without cycloheximide on fibroblasts. We then evaluated the allele frequency in the population using gnomAD. We identified an ∼2,600-bp SVA_E retrotransposon intronic insertion in ASPA in all 8 individuals. The insertion was found to be either homozygous or compound heterozygous trans with a known pathogenic variant in all individuals. RNA-seq indicated that the SVA_E insertion creates a novel splice acceptor site within intron 4 of ASPA that causes aberrant splicing and transcript degradation. Surprisingly, the frequency of this variant in population databases suggests that it is the most common pathogenic variant in ASPA and that it is present across ancestry groups. Our study identified the most common pathogenic variant in ASPA, which has been overlooked in 25 years of CD research. Considering this, it is important to ensure that all testing laboratories can detect this variant through diagnostic testing and carrier screening. Our study highlights a substantial blind spot in standard short-read diagnostic pipelines, which historically have missed or overlooked these types of insertions. It also shows the power of emerging technologies, such as LRS and RNA-seq, to identify new classes of variants for genetic disorders, including CD.
- 18 September 2022
- Published by Wiley in Human Mutation
- Vol. 43 (11) , 1531-1544
Long‐read sequencing for molecular diagnostics in constitutional genetic disorders
Long-read sequencing (LRS) has been around for more than a decade, but widespread adoption of the technology has been slow due to the perceived high error rates and high sequencing cost. This is changing due to the recent advancements to produce highly accurate sequences and the reducing costs. LRS promises significant improvement over short read sequencing in four major areas: (1) better detection of structural variation (2) better resolution of highly repetitive or nonunique regions (3) accurate long-range haplotype phasing and (4) the detection of base modifications natively from the sequencing data. Several successful applications of LRS have demonstrated its ability to resolve molecular diagnoses where short-read sequencing fails to identify a cause. However, the argument for increased diagnostic yield from LRS remains to be validated. Larger cohort studies may be required to establish the realistic boundaries of LRS's clinical utility and analytical validity, as well as the development of standards for clinical applications. We discuss the limitations of the current standard of care, and contrast with the applications and advantages of two major LRS platforms, PacBio and Oxford Nanopore, for molecular diagnostics of constitutional disorders, and present a critical argument about the potential of LRS in diagnostic settings.
- 18 September 2022
- Published by Wiley in Human Mutation
- Vol. 43 (11) , 1531-1544
Long‐read sequencing for molecular diagnostics in constitutional genetic disorders
Long-read sequencing (LRS) has been around for more than a decade, but widespread adoption of the technology has been slow due to the perceived high error rates and high sequencing cost. This is changing due to the recent advancements to produce highly accurate sequences and the reducing costs. LRS promises significant improvement over short read sequencing in four major areas: (1) better detection of structural variation (2) better resolution of highly repetitive or nonunique regions (3) accurate long-range haplotype phasing and (4) the detection of base modifications natively from the sequencing data. Several successful applications of LRS have demonstrated its ability to resolve molecular diagnoses where short-read sequencing fails to identify a cause. However, the argument for increased diagnostic yield from LRS remains to be validated. Larger cohort studies may be required to establish the realistic boundaries of LRS's clinical utility and analytical validity, as well as the development of standards for clinical applications. We discuss the limitations of the current standard of care, and contrast with the applications and advantages of two major LRS platforms, PacBio and Oxford Nanopore, for molecular diagnostics of constitutional disorders, and present a critical argument about the potential of LRS in diagnostic settings.
- 16 July 2021
- Published by Drexel University Libraries
Detection of clinically relevant copy-number variants from short-read sequencing data for genomic diagnostics
The overall goal of clinical genomic diagnostics is to identify pathogenic genetic variants that cause disease. Genetic variants can be classified into different subtypes based on the nature of the variant (sequence, copy-number, and structural variants), and current standard of care protocols require different diagnostic assays to detect these subtypes. Patients with suspected genetic disease often receive both chromosomal microarray array (CMA) testing for genome-wide copy number variant detection and exome sequencing for sequence variant detection to cover the spectrum of variant subtypes and sizes during their diagnostic odyssey. While short-read NGS testing, such as exome and genome, can detect both copy number and sequence variants, its implementation into the clinical lab has been hampered by both the lack of clinical standards and technical challenges concerning performance. Although not a currently offered clinical test, the identification of both copy number and sequencing variants from the same data would reduce the time to diagnosis, the costs involved, and significantly impact patient care. Using a cohort of 307 samples with clinical CMA and exome sequencing data, this thesis presents high quality, clinical-grade technical validation study and a new approach to tackling the major issue of false positives with current algorithms for CNV detection from exomes. A novel reproducibility framework was developed to assess the effect of control cohorts, and an R package for scalability in high-performance computing environments to analyze large exome sequencing cohorts. Application of the tools developed in this thesis to a cohort of 546 patients with rare pediatric disorders revealed eight novel diagnoses (1.5%) over their standard of care testing, and application to routine clinical epilepsy and hearing loss next-generation sequencing panels provided a minimum additional diagnostic yield of 2%. Over the next few years, genome sequencing is poised to become a first-tier diagnostic test, with the capability to detect all major classes of variation, including structural variants. Building on the exome work, I have developed a clinical-grade analytical workflow to integrate copy number and structural variants using 48 index samples with genome sequencing data and improved the false-positive rate. Application of this workflow to a cohort of 14 patients with clinically diagnosed Alagille Syndrome, but without a molecular diagnosis, revealed four novel diagnoses that were not detectable by the prior standard of care tests. These findings included a submicroscopic inversion in the gene JAG1 and a deletion in NOTCH2, the first-ever pathogenic copy number variant identified in this gene. Further, applying these methods to a cohort of 15 patients with nonsyndromic hearing loss revealed three novel diagnoses. The case series presented in this work argues the advantage of genome sequencing over the current standard of care tests for variants undetectable by their standard of care testing. Together, the frameworks presented in this thesis improved the current standard of care exome test and laid the groundwork for a future clinical test, genome sequencing. In addition, I demonstrated the clinical utility of the tools developed in this work showing how these approaches resulted in novel diagnoses and developed recommendations for broader application in clinical diagnostic settings. Keywords: copy-number variants, next-generation sequencing, Short-read sequencing, structural variation
- 16 July 2021
- Published by Drexel University Libraries
Detection of clinically relevant copy-number variants from short-read sequencing data for genomic diagnostics
The overall goal of clinical genomic diagnostics is to identify pathogenic genetic variants that cause disease. Genetic variants can be classified into different subtypes based on the nature of the variant (sequence, copy-number, and structural variants), and current standard of care protocols require different diagnostic assays to detect these subtypes. Patients with suspected genetic disease often receive both chromosomal microarray array (CMA) testing for genome-wide copy number variant detection and exome sequencing for sequence variant detection to cover the spectrum of variant subtypes and sizes during their diagnostic odyssey. While short-read NGS testing, such as exome and genome, can detect both copy number and sequence variants, its implementation into the clinical lab has been hampered by both the lack of clinical standards and technical challenges concerning performance. Although not a currently offered clinical test, the identification of both copy number and sequencing variants from the same data would reduce the time to diagnosis, the costs involved, and significantly impact patient care. Using a cohort of 307 samples with clinical CMA and exome sequencing data, this thesis presents high quality, clinical-grade technical validation study and a new approach to tackling the major issue of false positives with current algorithms for CNV detection from exomes. A novel reproducibility framework was developed to assess the effect of control cohorts, and an R package for scalability in high-performance computing environments to analyze large exome sequencing cohorts. Application of the tools developed in this thesis to a cohort of 546 patients with rare pediatric disorders revealed eight novel diagnoses (1.5%) over their standard of care testing, and application to routine clinical epilepsy and hearing loss next-generation sequencing panels provided a minimum additional diagnostic yield of 2%. Over the next few years, genome sequencing is poised to become a first-tier diagnostic test, with the capability to detect all major classes of variation, including structural variants. Building on the exome work, I have developed a clinical-grade analytical workflow to integrate copy number and structural variants using 48 index samples with genome sequencing data and improved the false-positive rate. Application of this workflow to a cohort of 14 patients with clinically diagnosed Alagille Syndrome, but without a molecular diagnosis, revealed four novel diagnoses that were not detectable by the prior standard of care tests. These findings included a submicroscopic inversion in the gene JAG1 and a deletion in NOTCH2, the first-ever pathogenic copy number variant identified in this gene. Further, applying these methods to a cohort of 15 patients with nonsyndromic hearing loss revealed three novel diagnoses. The case series presented in this work argues the advantage of genome sequencing over the current standard of care tests for variants undetectable by their standard of care testing. Together, the frameworks presented in this thesis improved the current standard of care exome test and laid the groundwork for a future clinical test, genome sequencing. In addition, I demonstrated the clinical utility of the tools developed in this work showing how these approaches resulted in novel diagnoses and developed recommendations for broader application in clinical diagnostic settings. Keywords: copy-number variants, next-generation sequencing, Short-read sequencing, structural variation
- 4 June 2020
- Published by Elsevier in Gastroenterology
- Vol. 159 (3) , 1068-1084.e2
Impaired Redox and Protein Homeostasis as Risk Factors and Therapeutic Targets in Toxin-Induced Biliary Atresia
- 4 June 2020
- Published by Elsevier in Gastroenterology
- Vol. 159 (3) , 1068-1084.e2
Impaired Redox and Protein Homeostasis as Risk Factors and Therapeutic Targets in Toxin-Induced Biliary Atresia
- Open Access
- 17 February 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-8
Exome Sequencing in Individuals with Isolated Biliary Atresia
Biliary atresia (BA) is a severe pediatric liver disease resulting in necroinflammatory obliteration of the extrahepatic biliary tree. BA presents within the first few months of life as either an isolated finding or with additional syndromic features. The etiology of isolated BA is unknown, with evidence for infectious, environmental, and genetic risk factors described. However, to date, there are no definitive causal genes identified for isolated BA in humans, and the question of whether single gene defects play a major role remains open. We performed exome-sequencing in 101 North American patients of European descent with isolated BA (including 30 parent-child trios) and considered several experimental designs to identify potentially deleterious protein-altering variants that may be involved in the disease. In a case-only analysis, we did not identify genes with variants shared among more than two probands, and burden tests of rare variants using a case-case control design did not yield significant results. In the trio analysis of 30 simplex families (patient and parent trios), we identified 66 de novo variants in 66 genes including potentially deleterious variants in STIP1 and REV1. STIP1 is a co-chaperone for the heat-shock protein, HSP90, and has been shown to have diverse functions in yeast, flies and mammals, including stress-responses. REV1 is known to be a key player in DNA repair pathway and to interact with HSP90. In conclusion, our results do not support the hypothesis that a simple genetic model is responsible for the majority of cases of isolated BA. Our finding of de novo variants in genes linked to evolutionarily conserved stress responses (STIP1 and REV1) suggests that exploration of how genetic susceptibility and environmental exposure may interact to cause BA is warranted.
- 17 February 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-8
Open AccessExome Sequencing in Individuals with Isolated Biliary Atresia
Biliary atresia (BA) is a severe pediatric liver disease resulting in necroinflammatory obliteration of the extrahepatic biliary tree. BA presents within the first few months of life as either an isolated finding or with additional syndromic features. The etiology of isolated BA is unknown, with evidence for infectious, environmental, and genetic risk factors described. However, to date, there are no definitive causal genes identified for isolated BA in humans, and the question of whether single gene defects play a major role remains open. We performed exome-sequencing in 101 North American patients of European descent with isolated BA (including 30 parent-child trios) and considered several experimental designs to identify potentially deleterious protein-altering variants that may be involved in the disease. In a case-only analysis, we did not identify genes with variants shared among more than two probands, and burden tests of rare variants using a case-case control design did not yield significant results. In the trio analysis of 30 simplex families (patient and parent trios), we identified 66 de novo variants in 66 genes including potentially deleterious variants in STIP1 and REV1. STIP1 is a co-chaperone for the heat-shock protein, HSP90, and has been shown to have diverse functions in yeast, flies and mammals, including stress-responses. REV1 is known to be a key player in DNA repair pathway and to interact with HSP90. In conclusion, our results do not support the hypothesis that a simple genetic model is responsible for the majority of cases of isolated BA. Our finding of de novo variants in genes linked to evolutionarily conserved stress responses (STIP1 and REV1) suggests that exploration of how genetic susceptibility and environmental exposure may interact to cause BA is warranted.
- Open Access
- 30 January 2020
- Published by Springer Nature in Genome Medicine
- Vol. 12 (1) , 1-11
A highly sensitive and specific workflow for detecting rare copy-number variants from exome sequencing data
Background: Exome sequencing (ES) is a first-tier diagnostic test for many suspected Mendelian disorders. While it is routine to detect small sequence variants, it is not a standard practice in clinical settings to detect germline copy-number variants (CNVs) from ES data due to several reasons relating to performance. In this work, we comprehensively characterized one of the most sensitive ES-based CNV tools, ExomeDepth, against SNP array, a standard of care test in clinical settings to detect genome-wide CNVs.Methods: We propose a modified ExomeDepth workflow by excluding exons with low mappability prior to variant calling to drastically reduce the false positives originating from the repetitive regions of the genome, and an iterative variant calling framework to assess the reproducibility. We used a cohort of 307 individuals with clinical ES data and clinical SNP array to estimate the sensitivity and false discovery rate of the CNV detection using exome sequencing. Further, we performed targeted testing of theSTRCgene in 1972 individuals. To reduce the number of variants for downstream analysis, we performed a large-scale iterative variant calling process with random control cohorts to assess the reproducibility of the CNVs.Results: The modified workflow presented in this paper reduced the number of total variants identified by one third while retaining a higher sensitivity of 97% and resulted in an improved false discovery rate of 11.4% compared to the default ExomeDepth pipeline. The exclusion of exons with low mappability removes 4.5% of the exons, including a subset of exons (0.6%) in disease-associated genes which are intractable by short-read next-generation sequencing (NGS). Results from the reproducibility analysis showed that the clinically reported variants were reproducible 100% of the time and that the modified workflow can be used to rank variants from high to low confidence. Targeted testing of 30 CNVs identified inSTRC, a challenging gene to ascertain by NGS, showed a 100% validation rate.Conclusions: In summary, we introduced a modification to the default ExomeDepth workflow to reduce the false positives originating from the repetitive regions of the genome, created a large-scale iterative variant calling framework for reproducibility, and provided recommendations for implementation in clinical settings.
- 30 January 2020
- Published by Springer Nature in Genome Medicine
- Vol. 12 (1) , 1-11
Open AccessA highly sensitive and specific workflow for detecting rare copy-number variants from exome sequencing data
Background: Exome sequencing (ES) is a first-tier diagnostic test for many suspected Mendelian disorders. While it is routine to detect small sequence variants, it is not a standard practice in clinical settings to detect germline copy-number variants (CNVs) from ES data due to several reasons relating to performance. In this work, we comprehensively characterized one of the most sensitive ES-based CNV tools, ExomeDepth, against SNP array, a standard of care test in clinical settings to detect genome-wide CNVs.Methods: We propose a modified ExomeDepth workflow by excluding exons with low mappability prior to variant calling to drastically reduce the false positives originating from the repetitive regions of the genome, and an iterative variant calling framework to assess the reproducibility. We used a cohort of 307 individuals with clinical ES data and clinical SNP array to estimate the sensitivity and false discovery rate of the CNV detection using exome sequencing. Further, we performed targeted testing of theSTRCgene in 1972 individuals. To reduce the number of variants for downstream analysis, we performed a large-scale iterative variant calling process with random control cohorts to assess the reproducibility of the CNVs.Results: The modified workflow presented in this paper reduced the number of total variants identified by one third while retaining a higher sensitivity of 97% and resulted in an improved false discovery rate of 11.4% compared to the default ExomeDepth pipeline. The exclusion of exons with low mappability removes 4.5% of the exons, including a subset of exons (0.6%) in disease-associated genes which are intractable by short-read next-generation sequencing (NGS). Results from the reproducibility analysis showed that the clinically reported variants were reproducible 100% of the time and that the modified workflow can be used to rank variants from high to low confidence. Targeted testing of 30 CNVs identified inSTRC, a challenging gene to ascertain by NGS, showed a 100% validation rate.Conclusions: In summary, we introduced a modification to the default ExomeDepth workflow to reduce the false positives originating from the repetitive regions of the genome, created a large-scale iterative variant calling framework for reproducibility, and provided recommendations for implementation in clinical settings.